|This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (July 2012)|
|Traded as||SIX: BION, FWB: BBZA|
|Founded||Schaffhausen, Switzerland (9 November 1993 )|
|Erich Hunzker (Chairman)|
|Products||Investment in biotechnology companies|
|CHF 391 million (2012)|
|Profit||(CHF 367.8 million) (2012)|
|Total assets||CHF 1.3763 billion (2012)|
|Total equity||CHF 1.234 billion (2012)|
BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.
At of September 30, 2013the six largest holdings in the BB Biotech portfolio were (in order of value): a 13% stake in Celgene; 11% of Isis Pharmaceuticals; 10.4% of Actelion; 9.6% of Gilead Sciences; 7.7% of Incyte and 4.5% of Vertex.
|This Swiss corporation or company article is a stub. You can help Wikipedia by expanding it.|